1
|
Tsoli M, Wadham C, Pinese M, Failes T, Joshi S, Mould E, Yin JX, Gayevskiy V, Kumar A, Kaplan W, Ekert PG, Saletta F, Franshaw L, Liu J, Gifford A, Weber MA, Rodriguez M, Cohn RJ, Arndt G, Tyrrell V, Haber M, Trahair T, Marshall GM, McDonald K, Cowley MJ, Ziegler DS. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. Cancer Biol Ther 2018; 19:1078-1087. [PMID: 30299205 PMCID: PMC6301829 DOI: 10.1080/15384047.2018.1491498] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Pediatric high grade gliomas (HGG) are primary brain malignancies that result in significant morbidity and mortality. One of the challenges in their treatment is inter- and intra-tumoral heterogeneity. Precision medicine approaches have the potential to enhance diagnostic, prognostic and/or therapeutic information. In this case study we describe the molecular characterization of a pediatric HGG and the use of an integrated approach based on genomic, in vitro and in vivo testing to identify actionable targets and treatment options. Molecular analysis based on WGS performed on initial and recurrent tumor biopsies revealed mutations in TP53, TSC1 and CIC genes, focal amplification of MYCN, and copy number gains in SMO and c-MET. Transcriptomic analysis identified increased expression of MYCN, and genes involved in sonic hedgehog signaling proteins (SHH, SMO, GLI1, GLI2) and receptor tyrosine kinase pathways (PLK, AURKA, c-MET). HTS revealed no cytotoxic efficacy of SHH pathway inhibitors while sensitivity was observed to the mTOR inhibitor temsirolimus, the ALK inhibitor ceritinib, and the PLK1 inhibitor BI2536. Based on the integrated approach, temsirolimus, ceritinib, BI2536 and standard therapy temozolomide were selected for further in vivo evaluation. Using the PDX animal model (median survival 28 days) we showed significant in vivo activity for mTOR inhibition by temsirolimus and BI2536 (median survival 109 and 115.5 days respectively) while ceritinib and temozolomide had only a moderate effect (43 and 75.5 days median survival respectively). This case study demonstrates that an integrated approach based on genomic, in vitro and in vivo drug efficacy testing in a PDX model may be useful to guide the management of high risk pediatric brain tumor in a clinically meaningful timeframe.
Collapse
Affiliation(s)
- Maria Tsoli
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Carol Wadham
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Mark Pinese
- b Prince of Wales Clinical School , University of New South Wales , Randwick , New South Wales , Australia
| | - Tim Failes
- c ACRF Drug Discovery Centre for Childhood Cancer, Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Swapna Joshi
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Emily Mould
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Julia X Yin
- d Kinghorn Centre for Clinical Genomics , Garvan Institute of Medical Research, University of New South Wales , Randwick, New South Wales , Australia.,e Cure Brain Cancer Neuro-Oncology Group , Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales , Randwick, New South Wales , Australia
| | - Velimir Gayevskiy
- f Bioinformatics and Cancer Genomics, Peter MacCallum Cancer Centre, The Sir Peter MacCallum Department of Oncology , The University of Melbourne, Melbourne , Victoria , Australia
| | - Amit Kumar
- f Bioinformatics and Cancer Genomics, Peter MacCallum Cancer Centre, The Sir Peter MacCallum Department of Oncology , The University of Melbourne, Melbourne , Victoria , Australia.,g Bioinformatics Division, The Walter & Eliza Hall Institute of Medical Research , Parkville, Melbourne , Victoria , Australia
| | - Warren Kaplan
- d Kinghorn Centre for Clinical Genomics , Garvan Institute of Medical Research, University of New South Wales , Randwick, New South Wales , Australia
| | - Paul G Ekert
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia.,h Cell Biology, Murdoch Children's Research Institute, Royal Children's Hospital , Parkville, Melbourne , Victoria , Australia
| | - Federica Saletta
- i Children's Cancer Research Unit, The Children's Hospital at Westmead , Westmead , NSW , Australia
| | - Laura Franshaw
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Jie Liu
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Andrew Gifford
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia.,j Anatomical Pathology, Prince of Wales Hospital , Randwick , New South Wales , Australia
| | - Martin A Weber
- j Anatomical Pathology, Prince of Wales Hospital , Randwick , New South Wales , Australia
| | - Michael Rodriguez
- j Anatomical Pathology, Prince of Wales Hospital , Randwick , New South Wales , Australia
| | - Richard J Cohn
- k Kids Cancer Centre, Sydney Children's Hospital , Randwick , New South Wales , Australia
| | - Greg Arndt
- c ACRF Drug Discovery Centre for Childhood Cancer, Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Vanessa Tyrrell
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Michelle Haber
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia
| | - Toby Trahair
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia.,k Kids Cancer Centre, Sydney Children's Hospital , Randwick , New South Wales , Australia
| | - Glenn M Marshall
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia.,k Kids Cancer Centre, Sydney Children's Hospital , Randwick , New South Wales , Australia
| | - Kerrie McDonald
- b Prince of Wales Clinical School , University of New South Wales , Randwick , New South Wales , Australia.,e Cure Brain Cancer Neuro-Oncology Group , Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales , Randwick, New South Wales , Australia
| | - Mark J Cowley
- d Kinghorn Centre for Clinical Genomics , Garvan Institute of Medical Research, University of New South Wales , Randwick, New South Wales , Australia.,l St Vincent's Clinical School , University of New South Wales , Randwick , New South Wales , Australia
| | - David S Ziegler
- a Children's Cancer Institute, Lowy Cancer Research Centre , University of New South Wales , Randwick , New South Wales , Australia.,k Kids Cancer Centre, Sydney Children's Hospital , Randwick , New South Wales , Australia
| |
Collapse
|
4
|
Cruceru ML, Enciu AM, Popa AC, Albulescu R, Neagu M, Tanase CP, Constantinescu SN. Signal transduction molecule patterns indicating potential glioblastoma therapy approaches. Onco Targets Ther 2013; 6:1737-49. [PMID: 24348050 PMCID: PMC3848931 DOI: 10.2147/ott.s52365] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE The expression of an array of signaling molecules, along with the assessment of real-time cell proliferation, has been performed in U87 glioma cell line and in patients' glioblastoma established cell cultures in order to provide a better understanding of cellular and molecular events involved in glioblastoma pathogenesis. Experimental therapy was performed using a phosphatidylinositol-3'-kinase (PI3K) inhibitor. PATIENTS AND METHODS xMAP technology was employed to assess expression levels of several signal transduction molecules and real-time xCELLigence platform for cell behavior. RESULTS PI3K inhibition induced the most significant effects on global signaling pathways in patient-derived cell cultures, especially on members of the mitogen-activated protein-kinase family, P70S6 serine-threonine kinase, and cAMP response element-binding protein expression and further prevented tumor cell proliferation. CONCLUSION The PI3K pathway might be a prime target for glioblastoma treatment.
Collapse
Affiliation(s)
- Maria Linda Cruceru
- Carol Davila University of Medicine and Pharmacy, Department of Cellular and Molecular Medicine, Bucharest, Romania
| | - Ana-Maria Enciu
- Carol Davila University of Medicine and Pharmacy, Department of Cellular and Molecular Medicine, Bucharest, Romania ; Victor Babes National Institute of Pathology, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Adrian Claudiu Popa
- Carol Davila University of Medicine and Pharmacy, Department of Cellular and Molecular Medicine, Bucharest, Romania ; Army Centre for Medical Research, Bucharest, Romania
| | - Radu Albulescu
- Victor Babes National Institute of Pathology, Bucharest, Romania ; National Institute for Chemical Pharmaceutical R&D, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Monica Neagu
- Victor Babes National Institute of Pathology, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Cristiana Pistol Tanase
- Victor Babes National Institute of Pathology, Bucharest, Romania ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Stefan N Constantinescu
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium ; Ludwig Institute for Cancer Research, Brussels, Belgium ; Operational Sectorial Programme for Competitive Economic Growth Canbioprot at Victor Babes National Institute of Pathology, Bucharest, Romania
| |
Collapse
|